Literature DB >> 1093966

Experimental Escherichia coli O6 pyelonephritis in rabbits. Effect on O6 antibody quantity and avidity of prior immunization with E. coli O2 bacteria.

S Ahlstedt, B Kaijser.   

Abstract

Haematogenous pyelonephritis was induced in rabbits using Escherichia coli 06:K13:H1 bacteria and the amounts and avidities of antibodies to the 06 antigen were analysed by the ammonium sulphate precipitation technique of Farr. In a group of six animals preimmunized with E. coli 02:K2ab:H1, five developed pyelonephritis and one pyelitis, as determined by histological examination. All aminals showed a considerable antibody response to E. coli 06 antigen during the infection. The animal with pyelitis gave a slightly smaller response than the others. The antibody avidity showed a pronounced variation. In a second group of six rabbits not preimmunized, five animals developed pyelonephritis. The titres of antibodies against E. coli 06 antigen increased during the infection inall of the six animals. However, the increase was significantly smaller than for the animals preimmunized with E. coli 02:K2ab:H1 (P smaller than 0.01). The pattern of the antibody avidities in this group was also heterogenous. The results are consistent with previous findings that exposure to serologically heterologous E. coli bacteria can enhance the development of the homologous antibody titres. This could be of relevance for serological diagnostic work as well as in the determination of the protective capacity of the antibody.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1093966      PMCID: PMC1445913     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  [Experimental pyelonephritis. II. Appearance of contracted pyelonephrotic kidney in rabbits].

Authors:  V PRAT; D BENESOVA; F CERVINKA
Journal:  Cas Lek Cesk       Date:  1959-04-10

2.  A quantitative immunochemical measure of the primary interaction between I BSA and antibody.

Authors:  R S FARR
Journal:  J Infect Dis       Date:  1958 Nov-Dec       Impact factor: 5.226

3.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

4.  Protective capacity of antibodies against E. coli O antigen with special reference to the avidity.

Authors:  S Ahlstedt; J Holmgren; L A Hanson
Journal:  Int Arch Allergy Appl Immunol       Date:  1974

5.  Experimental hematogenous pyelonephritis due to Escherichia coli in rabbits: the antibody response and its protective capacity.

Authors:  B Kaijser; S Olling
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

6.  Local antibody production in experimental pyelonephritis: amount, avidity, and immunoglobulin class.

Authors:  J Smith; J Holmgren; S Ahlstedt; L A Hanson
Journal:  Infect Immun       Date:  1974-09       Impact factor: 3.441

7.  The protective effect against E. coli of O and K antibodies of different immunoglobulin classes.

Authors:  B Kaijser; J Holmgren; L A Hanson
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

8.  Enhancement of the IgG antibody production to Escherichia coli O antigen by prior exposure to serologically different E. coli bacteria.

Authors:  J Holmgren; S Ahlstedt
Journal:  Immunology       Date:  1974-01       Impact factor: 7.397

9.  Studies on hemagglutination and hemolysis by escherichia coli antisera.

Authors:  E NETER; L F BERTRAM; D A ZAK; M R MURDOCK; C E ARBESMAN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

10.  Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide.

Authors:  A G JOHNSON; S GAINES; M LANDY
Journal:  J Exp Med       Date:  1956-02-01       Impact factor: 14.307

View more
  1 in total

1.  Protective capacity of antibodies against Escherichia coli and K antigens.

Authors:  B Kaijser; S Ahlstedt
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.